CMED
14.1.2016 16:42:58 CET | Business Wire | Press release
Cmed Clinical Services, an eClinical technology-led CRO, announced today the appointment of Graham Belgrave as Chief Operations Officer.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160114005858/en/
In this role, Belgrave will be responsible for the company’s day-to-day clinical operating activities. He will be based in the UK and brings to Cmed a wealth of experience in global Clinical Development, Strategy, Clinical Operations, Outsourcing and Project Management.
“We are excited to welcome Graham Belgrave to our organization” said Dr. David Connelly, Cmed’s CEO. “Graham has a great track record over many years in the pharmaceutical industry and his breadth of clinical development experience across many therapy areas in Phases I-IV combined with his strong leadership skills will complement and strengthen our existing senior management team. He will be a valuable asset to Cmed as we continue to drive growth”.
Belgrave joins Cmed from German Headquartered pharmaceutical company Grunenthal GmbH, where he was SVP Global Head Clinical Development, Science and Operations. Prior this, he has worked at companies such as Vernalis, Pfizer and GSK, and has worked in consultancy and interim management positions, including in Oncology at Roche. From a career spanning over 30 years, he has built a strong clinical operations and drug development background as well as successfully leading outsourcing and vendor management organizations. He is a Fellow of the Royal Society of Medicine (Oncology and clinical research sections) and he is an experienced chairperson, speaker and committee member of various industry congresses and symposia.
- ends -
About Cmed
Cmed provides innovative e-clinical data capture and management technologies with CRO capabilities allowing sponsors to make faster, better decisions. Cmed’s technology uniquely improves workflow processes including eSource, remote monitoring, and risk based monitoring between sites, investigators, monitors, data managers, biostatisticians, and sponsors allowing easier access to the data anytime, for any trial, anywhere. For more information visit www.cmedresearch.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160114005858/en/
Contact:
Cmed
Anna Forster
aforster@cmedresearch.com
+44(0)1403-755050
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
illumynt Appoints Anthony Giannetti as Senior Vice President of Global Operations16.7.2026 13:00:00 CEST | Press release
Seasoned operations leader brings two decades of OEM and ITAD experience, including Dell, Apple, and Microsoft, as illumynt scales its global AI hardware lifecycle platform illumynt, a technology-driven leader in AI hardware lifecycle recovery and IT asset disposition (ITAD), today announced that Anthony "Tony" Giannetti has joined the company as Senior Vice President of Global Operations, effective July 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716696044/en/ Anthony Giannetti, SVP Global Operations Giannetti brings more than two decades of operations and supply chain leadership from some of the technology industry's largest OEMs, including Dell, where he managed reverse supply chain operations, and Apple and Microsoft, where he held additional operations leadership roles. His background spans production engineering, reverse logistics, and large-scale operational management, disciplines directly relevant to
Compvide™ Announces Strategic Collaboration with OpZira™ to Accelerate Growth and Advance the CIMED™ Platform16.7.2026 12:47:00 CEST | Press release
Compvide, Inc., a biotechnology company pioneering functional complement intelligence through innovative diagnostics and immune-response monitoring, today announced a strategic collaboration with OpZira, Inc. to support the company’s continued growth and accelerate development of its proprietary CIMED platform. Through the collaboration, OpZira will provide comprehensive operational support across clinical, customer care, finance, manufacturing, marketing, quality, and regulatory functions,” stated Clark Tedford, Ph.D., President and CEO, OpZira, Inc. “By leveraging OpZira’s established operational infrastructure and expertise, Compvide can remain focused on advancing its scientific innovation while expanding its capabilities in complement-focused diagnostics and translational medicine.” “Partnering with an experienced organization that understands the unique needs of emerging healthcare companies is an important step for Compvide as we continue building the company,” said Sadam Yaseen
Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy16.7.2026 12:35:00 CEST | Press release
Post-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and distinct from conventional conceptions of psychotherapyFindings published in the Journal of Psychopharmacology Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder (PTSD). Documented speech production between participants and support providers during treatment administration sessions showed minimal interaction. Monitoring and support were linked by patients to presence, availability, reassurance and validation. The limited and non-directive nature of these interactions distinguishes this fo
Circus Commences Operations with Ukrainian Ground Forces16.7.2026 12:04:00 CEST | Press release
Circus SE (WKN: A2YN35 / ISIN: DE000A2YN355 / XETRA: CA1), today announces the commencement of live operations of its robotic-based troop supply technology with the 3rd Army Corps of the Ukrainian Ground Forces in the Kyiv area – marking the first ever use of autonomous meal supply systems within an active conflict environment. Ahead of deployment, Circus received regulatory certification from the State Service of Ukraine for Food Safety and Consumer Protection. This certification confirms compliance with all applicable health, quality, and safety standards required to import the company's technology into Ukraine, and clears the path for operational use at scale. Soldiers are supplied using Circus's full technology stack, comprising the hardware system, AI-controlled software, and proprietary ingredient infrastructure that underpins autonomous meal production in military environments. The deployment marks Circus's entry into the Ukrainian market and the operational commencement of the
Fourthline and Veridas Join Forces to Fight Identity Fraud with a Global Identity Platform16.7.2026 11:21:00 CEST | Press release
Founded in Europe, now with global reach: backed by European investors and bringing bank-grade European compliance standards to markets worldwide Customer Value: A streamlined, end-to-end user experience that protects identity across the entire customer lifetime and helps customers grow revenue safely and compliantly. The Expected Result:Fourthline and Veridas are joining forces to create a global bank-grade identity platform: sovereign AI, modular compliance, and proprietary anti-fraud and biometric technology across Europe, Latin America, and the US. One trusted partner for end-to-end KYC, AML, and Identity compliance. Terms of Deal: Following completion of the merger, Veridas shareholders (including BBVA) will continue as shareholders in the combination, and the transaction will be partially funded by existing Fourthline investor Finch Capital and new investors including Rabo Investments, the captive investment arm of Rabobank. Expected close is in the second half of 2026, pending c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom